

Sr. No	Particulars	3 months ended 30.09.2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	8
	Disposed of during the quarter	8
	Remaining unresolved at the end of the quarter	Nil

Notes :

1 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(₹ In Lacs)

Net Sales and Income from Operations	Quarter ended 30.09.2015 (Unaudited)	Quarter ended 30.06.2015 (Unaudited)	Quarter ended 30.09.2014 (Unaudited)	Half year ended 30.09.2015 (Unaudited)	Half year ended 30.09.2014 (Unaudited)	Year ended 31.03.2015 (Audited)
India	14,665	13,217	14,469	27,882	27,269	53,208
Outside India	10,102	8,380	8,173	18,482	15,168	31,682
Total	24,767	21,597	22,642	46,364	42,437	84,890

2 The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 30th October, 2015.

3 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th September, 2015.

4 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

5 STATEMENT OF ASSETS AND LIABILITIES

(₹ In Lacs)

Sr. No	Particulars	As at 30/09/2015 (Unaudited)	As at 31/03/2015 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholder's Funds		
	(a) Share Capital	1,843	1,843
	(b) Reserves & Surplus	54,295	49,995
	Sub-total - Shareholder's Fund	56,138	51,838
2	Non-Current Liabilities		
	(a) Long Term Borrowings	3,102	1,285
	(b) Deferred Tax Liabilities (Net)	2,611	2,701
	(c) Other Long Term Liabilities	972	969
	(d) Long Term Provision	1,692	1,503
	Sub-total - Non Current Liabilities	8,377	6,458
3	Current Liabilities		
	(a) Short Term Borrowings	7,150	7,305
	(b) Trade Payable	13,257	11,863
	(c) Other Current Liabilities	7,659	4,088
	(d) Short Term Provision	714	2,602
	Sub-total - Current Liabilities	28,780	25,858
	TOTAL - EQUITY AND LIABILITIES	93,295	84,154
B	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets	41,734	40,213
	(b) Non Current Investments	54	64
	(c) Long Term Loans & Advances	6,583	5,734
	Sub-total - Non Current Assets	48,371	46,011
2	Current Assets		
	(a) Inventories	16,480	14,620
	(b) Trade Receivables	18,734	15,364
	(c) Cash and Cash Equivalents	1,118	1,528
	(d) Short Term Loans and Advances	8,376	6,589
	(e) Other Current Assets	216	42
	Sub-total - Current Assets	44,924	38,143
	TOTAL ASSETS	93,295	84,154

By Order of the Board
For Indoco Remedies Ltd

sd/-

Suresh G. Kare
Chairman

Place : Mumbai
Date : 30th October, 2015



PATKAR & PENDSE

CHARTERED ACCOUNTANTS

204, Chartered House, 297/298, Dr. Cawasji Hormasji Street,
Next to Queens Road Church, Marine Lines, Mumbai - 400 002.

Tel. : 2206 0309 / 2206 0868 / 6522 4568

E-mail : bmpco@rediffmail.com

LIMITED REVIEW REPORT

The Board of Directors,
M/s. INDOCO REMEDIES LIMITED
Mumbai

Independent Auditors Limited Review Report

1. We have reviewed the accompanying statement of Unaudited financial results of **M/s. Indoco Remedies Limited** ("the Company") for the Quarter and Half year ended 30th September, 2015 ("the statement"), being submitted by the Company pursuant to the requirement of Clause 41 of the Listing agreements with the Stock Exchange except for the disclosures in Part II – Selective Information referred to in paragraph 4 below. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion
3. Based on our reviews conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles, generally accepted in India has not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement with the Stock Exchange, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. Further we also repeat that we have traced the number of shares as well as the percentage of shareholding in respect of the aggregate amount of public shareholding and the number of shares as well as the percentage of shares pledged encumbered and non encumbered in respect of the aggregate amount of promoter and promoter group shareholding in terms of clause 35 of the Listing Agreement with the Stock Exchange and the particulars relating to investor complaints disclosed in Part –II- select Information for the Quarter and Half year Ended 30th September, 2015 of the Statement, from the details furnished by the Management/Registrars.

For Patkar & Pendse
Chartered Accountants



Partner

Place : Mumbai

Date : 30th October, 2015